Miles C Andrews

17PUBLICATIONS
159CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsGene and molecular therapyRecommender systems
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Oct 09, 2025
Expansion of a circulating Ki67-positive effector T-cell population following combined PD-1 and CTLA-4 blockade for melanoma is predictive of treatment response.

Jack M Edwards, Sashendra Senthi, Robin Smith

|Jun 30, 2025
Prospective Isolation According to Melanin Pigment Content of Melanoma Cells With Heterogeneous Potentials for Disease Propagation.

Clare Fedele, Gamze Kuser-Abali, Ralph Rossi

|Feb 06, 2025
Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types.

David R Gandara, Neeraj Agarwal, Shilpa Gupta

|Jun 07, 2024
Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma.

Miles C Andrews, Gerald Li, Ryon P Graf

|Sep 11, 2023
Design, optimisation and standardisation of a high-dimensional spectral flow cytometry workflow assessing T-cell immunophenotype in patients with melanoma.

Jack M Edwards, Miles C Andrews, Hayley Burridge

|Mar 11, 2023
UHRF1/UBE2L6/UBR4-mediated ubiquitination regulates EZH2 abundance and thereby melanocytic differentiation phenotypes in melanoma.

Gamze Kuser-Abali, Youfang Zhang, Pacman Szeto

Pageof 3

Frequent Collaborators

9 joint publications

Jennifer Wargo

8 joint publications

Michael A Davies

7 joint publications

P Andrew Futreal

7 joint publications

Alexander J Lazar